Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholder Deficit

v3.19.3
Condensed Consolidated Statement of Changes in Stockholder Deficit - USD ($)
Common Stock [Member]
Additional Paid-In-Capital [Member]
Deferred Compensation [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 122,675 $ 56,401,069 $ (10,125) $ (57,919,096) $ (1,405,477)
Balance, shares at Dec. 31, 2017 122,674,516        
Common stock grants to independent directors $ 907 199,093 200,000
Common stock grants to independent directors, shares 906,774        
Deferred compensation 10,125 10,125
Deferred compensation, shares        
Cardax 2018 Warrant Exchange Offering $ 9,600 1,234,437 1,244,037
Cardax 2018 Warrant Exchange Offering, shares 9,600,286        
Stock option exercises - cashless $ 157 (157)
Stock option exercises - cashless, shares 156,997        
Stock based compensation - options 233,124 233,124
Net loss (3,076,873) (3,076,873)
Balance at Sep. 30, 2018 $ 133,339 58,067,566 (60,995,969) (2,795,064)
Balance, shares at Sep. 30, 2018 133,338,573        
Balance at Dec. 31, 2017 $ 122,675 56,401,069 (10,125) (57,919,096) $ (1,405,477)
Balance, shares at Dec. 31, 2017 122,674,516        
Stock option exercises - cashless, shares         200,000
Balance at Dec. 31, 2018 $ 133,889 58,274,038 (61,943,318) $ (3,535,391)
Balance, shares at Dec. 31, 2018 133,888,573        
Balance at Jun. 30, 2018 $ 123,301 56,653,005 (60,067,081) (3,290,775)
Balance, shares at Jun. 30, 2018 123,300,787        
Common stock grants to independent directors $ 438 87,062 87,500
Common stock grants to independent directors, shares 437,500        
Deferred compensation
Deferred compensation, shares        
Cardax 2018 Warrant Exchange Offering $ 9,600 1,234,437 1,244,037
Cardax 2018 Warrant Exchange Offering, shares 9,600,286        
Stock based compensation - options 93,062 93,062
Net loss (928,888) (928,888)
Balance at Sep. 30, 2018 $ 133,339 58,067,566 (60,995,969) (2,795,064)
Balance, shares at Sep. 30, 2018 133,338,573        
Balance at Dec. 31, 2018 $ 133,889 58,274,038 (61,943,318) (3,535,391)
Balance, shares at Dec. 31, 2018 133,888,573        
Common stock grants to independent directors $ 1,627 260,873 $ 262,500
Common stock grants to independent directors, shares 1,627,191        
Stock option exercises - cashless, shares        
Stock based compensation - options 257,875 $ 257,875
Common stock grant to service providers $ 113 14,287 14,400
Common stock grant to service providers, shares 112,500        
Restricted stock issuances $ 1,633 243,367 245,000
Restricted stock issuances, shares 1,633,330        
Issuance of warrants attached to a convertible note 141,435 141,435
Net loss (3,650,740) (3,650,740)
Balance at Sep. 30, 2019 $ 137,262 59,191,875 (65,594,058) (6,264,921)
Balance, shares at Sep. 30, 2019 137,261,594        
Balance at Jun. 30, 2019 $ 136,641 58,908,648 (64,160,432) (5,115,143)
Balance, shares at Jun. 30, 2019 136,640,761        
Common stock grants to independent directors $ 583 86,917 87,500
Common stock grants to independent directors, shares 583,333        
Stock based compensation - options 84,875 84,875
Common stock grant to service providers $ 38 3,300 3,338
Common stock grant to service providers, shares 37,500        
Issuance of warrants attached to a convertible note 108,135 108,135
Net loss (1,433,626) (1,433,626)
Balance at Sep. 30, 2019 $ 137,262 $ 59,191,875 $ (65,594,058) $ (6,264,921)
Balance, shares at Sep. 30, 2019 137,261,594